1. Okamoto Y, Hirano M, Morino K, Kajita MK, Nakaoka S, Tsuda M, Sugimoto KJ, Tamaki S, Hisatake J, Yokoyama H, Igarashi T, Shinagawa A, Sugawara T, Hara S, Fujikawa K, Shimizu S, Yujiri T, Wakita H, Nishiwaki K, Tojo A, Aihara K. Early dynamics of chronic myeloid leukemia on nilotinib predicts deep molecular response. NPJ Syst Biol Appl 2022; 8(1): 39. Epub 2022 Oct 13.
2. Yanada M, Matsuda K, Ishii H, Fukuda T, Ozeki K, Ota S, Tashiro H, Uchida N, Kako S, Doki N, Kawakita T, Onishi Y, Takada S, Kondo Y, Tanaka J, Kanda Y, Atsuta Y, Yano S. Allogeneic Hematopoietic Cell Transplantation for Patients with Relapsed Acute Promyelocytic Leukemia. Transplant Cell Ther. 2022 Dec;28(12):847.e1-847.e8.
3. Yanada M, Yamasaki S, Konuma T, Mizuno S, Uchida N, Onai D, Fukuda T, Tanaka M, Ozawa Y, Eto T, Ikegame K, Sawa M, Katayama Y, Kawakita T, Onizuka M, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Age and allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia. Int J Hematol 2022 doi: 10.1007/s12185-022-03486-7. Online ahead of print
4. Konuma T, Harada K, Kondo T, Masuko M, Uchida N, Yano S, Kawakita T, Onizuka M, Ota S, Sakaida E, Miyakoshi S, Ozawa Y, Imamura Y, Kimura T, Kanda Y, Fukuda T, Atsuta Y, Yanada M. Salvage single-unit unrelated cord blood transplantation for graft failure following initial allogeneic transplantation in adult acute myeloid leukemia: trends in outcomes over the past 20 years. Bone Marrow Transplant 2022 doi: 10. 1.38/s41409-022-01840-1. Online ahead of print
5. Miyazaki Y, Kiguchi T, Sato S, Usuki K, Ishiyama K, Ito Y, Suzuki T, Taguchi J, Chiba S, Dobashi N, Tomita A, Harada H, Handa H, Horiike S, Maeda T, Matsuda M, Ichikawa M, Hata T, Honda S, Iyama S, Suzushima H, Moriuchi Y, Kurokawa T, Yokota K, Ohtake S, Yamauchi T, Matsumura I, Kiyoi H, Naoe T; Japan Adult Leukemia Study Group. Prospective comparison of 5- and 7-day administration of azacitidine for myelodysplastic syndromes: a JALSG MDS212 trial. Int J Hematol 2022 Aug; 116(2): 228-38.
6. Suzuki T, Terada M, Machida R, Kataoka T, Ito Y, Kataoka K, Maruyama D, Nagai H, Lymphoma Study Group of the Japan Clinical Oncology Group, Randomized phase III study of daratumumab versus bortezomib plus daratumumab as maintenance therapy after D-MPB for transplant-ineligible patients with untreated multiple myeloma (JCOG1911, B-DASH study), Japanese Journal of Clinical Oncology, Volume 53, Issue 4, April 2023, Pages 349-354, https://doi.org/10.1093/jjco/hyac198
7. Hatta S, Fukuhara S, Fujino T, Saito Y, Ito Y, Makita S, Munakata W, Suzuki T, Maruyama D, Kusumoto M, ＆ Izutsu K. (2022). The role of surveillance computed tomography in patients with follicular lymphoma. Therapeutic advances in hematology, 13, 20406207221095963. https://doi.org/10.1177/20406207221095963
8. Suzuki K, Mizuno S, Shimazu Y, Fuchida SI, Hagiwara S, Itagaki M, Nishiwaki K, Hangaishi A, Karasuno T, Kikuchi T, Shimizu M, Nishikawa A, Kobayashi T, Sunami K, Hiramoto N, Uchiyama H, Maruyama Y, Kanda Y, Ichinohe T, Atsuta Y, Yano S, Kawamura K; Working Group of the Japan Society; for Transplantation and Cellular Therapy. Tandem autologous stem cell transplantation in elderly patients with myeloma: A multicenter retrospective analysis. Eur J Haematol. 2023 Apr;110(4):444-454. Epub 2023 Jan 17.
9. Suzuki K, Matsumoto M, Hiramatsu Y, Takezako N, Tamai Y, Suzuki K. Once Monthly Elotuzumab and Lenalidomide Plus Dexamethasone for Multiple Myeloma: A Multicenter Observation Study.Acta Haematol. 2023; 14682): 125-36.
10. Miyamoto-Nagai Y, Mimura N, Tsukada N, Aotsuka N, Ri M, Katsuoka Y, Wakayama T, Suzuki R, Harazaki Y, Matsumoto M, Kumagai K, Miyake T, Ozaki S, Shono K, Tanaka H, Shimura A, Kuroda Y, Sunami K, Suzuki K, Yamashita T, Shimizu K, Murakami H, Abe M, Nakaseko C, Sakaida E. Outcomes of poor peripheral blood stem cell mobilizers with multiple myeloma at the first mobilization: A multicenter retrospective study in Japan. EJHaem. 2022; 3(3): 838-48.
11. Kurosawa S, Yamaguchi T, Mori A, Matsuura T, Masuko M, Murata M, Tashiro H, Kako S, Satake A, Hagihara M, Ota S, Saito T, Kagawa K, Matsuo Y, Itonaga H, Uoshima N, Yamaguchi H, Naito K, Takahashi M, Fukuda T. Incidence and predictors of recurrent sick leave in survivors who returned to work after allogeneic hematopoietic cell transplantation. J Cancer Surviv. 2022 Sep 1. doi: 10.1007/s11764-022-01250-8. Online ahead of print.
12. Mizuta S, Ugai T, Kato H, Doki N, Ota S, Kawakita T, Katayama Y, Kurokawa M, Nakamae H, Yano S, Nawa Y, Kanda Y, Fukuda T, Atsuta Y, Kako S. Propensity score matching/reweighting analysis comparing autologous and allogeneic stem cell transplantation for B-lineage acute lymphoblastic leukemia; International Journal of Hematology. 2022 2022.09;116(3):393-400.
13. Onishi C, Nishikori M, Yakushijin K, Kurahashi S, Nakazawa H, Takamatsu Y, Hashimoto Y, Tatetsu H, Nawa Y, Yoshida M, Kobayashi T, Oyake T, Yano S, Oride A, Suzuki R. Lymphoma during pregnancy in Japan: a multicenter retrospective cohort study. International Journal of Hematology. 2022 2022.03;115(3):382-390.. Cited in: Pubmed; PMID W408250010Yano S. [Hematologic Malignancies/Pediatric Malignancies The Leading Edge of Onco-Cardiology in Hematological Malignancies]. Gan To Kagaku Ryoho. 2021;48(5):649-650.
14. Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group. Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group. Int J Hematol. 2021 Mar;113(3):395-403.
15. Hayashi K, Tamura M, Nagasaki E, Yoshii Y, Ishigaki T, Kazama T, Kamio M, Nogi H, Toriumi Y, Takeyama H, Yano S. A Retrospective Analysis of Perioperative Chemotherapy and Coronavirus Disease in Patients With Breast Cancer. Anticancer Res. 2021;41(4):2193-2195.
16. Ito Y, Nishiwaki K, Matsuzawa H, Hattori D, Tanoue S, Suzuki K, Katori M, Hirooka S, Masuoka H, Yano S. A difficult case of angioimmunoblastic T-cell lymphoma with Epstein-Barr virus-negative large mononuclear atypical cells. J Clin Exp Hematop. 2021;61(4):224-226.
17. Kamitani I, Saito T, Yokoyama H, Nakano A, Ishii H, Tanoue S, Hattori D, Oshima S, Ishii S, Gunji T, Fukushima R, Katsube A, Shimada T, Nishiwaki K, Dobashi N, Yano S. Successful bridge therapy of gilteritinib to cord blood transplantation in relapsed acute myeloid leukemia after bone marrow transplantation. J Infect Chemother. 2021 Apr;27(4):639-641. eng. Epub 2020/11/21. doi:10.1016/j.jiac.2020.11.003. Cited in: Pubmed; PMID 33214069.
18. Nagasaki E, Kudo R, Tamura M, Hayashi K, Uwagawa T, Kijima Y, Nogi H, Takeyama H, Suzuki M, Nishikawa M, Yano S, Kobayashi T. Long-term outcomes of oligometastatic breast cancer patients treated with curative intent: an updated report. Breast Cancer. 2021;28(5):1051-1061.
19. Yano S, Yokoyama H, Yanada M, Mori J, Aoki J, Ohashi K, Kanomori H, Ozawa Y, Sawa M, Nakamae H, Eto T, Ohta S, Tanaka J, Ichinohe T, Atsuta Y, Takami A: Role of alternative donor allogeneic hematopoietic stem cell transplantation in patients with intermediate- or poor-risk acute myeloid leukemia in first complete remission. Bone Marrow Transplant 2019 54; 2004-2012.
20. Suzuki K, Tsukada N, Nishimura N, Nagata Y, Okazuka K, Mishima Y, Yokoyama M, Nishiwaki K, Ishida T, Yano S, Terui Y, Suzuki K: Bortezomib, lenalidomide, and dexamethasone in transplant-eligible newly diagnosed multiple myeloma patients: a multicenter retrospective comparative analysis. Int J Hematol 2020 111;103-111.
21. Kawashima M, Carreras J, Higuchi H, Kotaki R, Hoshina T, Okuyama K, Suzuki N, Kakizaki M, Miyatake Y, Ando K, Nakayama M, Umezu S, Horie R, Higuchi Y, Katagiri K, Goyama S, Kitamura T, Chamoto K, Yano S, Nakamura N, Kotani A. PD-L1/L2 protein levels rapidly increase on monocytes via trogocytosis from tumor cells in classical Hodgkin lymphoma. Leukemia. 2020 Feb 24. [Epub ahead of print].
22. Nakasone H, Kako S, Mori T, Takahashi S, Onizuka M, Fujiwara SI, Sakura T, Sakaida E, Yokota A, Aotsuka N, Hagihara M, Tsukada N, Hatta Y, Usuki K, Watanabe R, Gotoh M, Fujisawa S, Yano S, Kanamori H, Okamoto S, Kanda Y. Stopping tyrosine kinase inhibitors started after allogeneic HCT in patients with Philadelphia chromosome-positive leukemia. Bone Marrow Transplant. 2021 Jan 8. doi: 10.1038/s41409-020-01206-5. Online ahead of print.
23. Yanada M, Konuma T, Yamasaki S, Kondo T, Fukuda T, Shingai N, Sawa M, Ozawa Y, Tanaka M, Uchida N, Nakamae H, Katayama Y, Matsuoka KI, Kimura T, Kanda Y, Ichinohe T, Atsuta Y, Yano S. Relapse of acute myeloid leukemia after allogeneic hematopoietic cell transplantation: clinical features and outcomes. Bone Marrow Transplant. 2020 Dec 2. doi: 10.1038/s41409-020-01163-z. Online ahead of print.
24. Harada K, Fuji S, Seo S, Uchida N, Kawakita T, Yano S, Ozawa Y, Yoshioka S, Onishi Y, Noguchi Y, Onizuka M, Matsuhashi Y, Kimura T, Ichinohe T, Atsuta Y; Transplant Complications Working Group of the Japan Society for Hematopoietic Cell Transplantation; GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation, Terakura S, Nakasone H. Comparison of immunosuppressant regimens in salvage cord blood transplantation for graft failure after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2021 Feb;56(2):400-410.
25. Yanada M, Konuma T, Mizuno S, Saburi M, Shinohara A, Tanaka M, Marumo A, Sawa M, Uchida N, Ozawa Y, Onizuka M, Yoshioka S, Nakamae H, Kondo T, Kimura T, Kanda J, Fukuda T, Atsuta Y, Nakasone H, Yano S. Predicting non-relapse mortality following allogeneic hematopoietic cell transplantation during first remission of acute myeloid leukemia. Bone Marrow Transplant. 2021 Feb;56(2):387-394.
26. Mizuno S, Yanada M, Kawamura K, Masuko M, Uchida N, Ozawa Y, Iwato K, Ohashi K, Ikegame K, Kim SW, Tanaka M, Eto T, Kanda Y, Fukuda T, Atsuta Y, Yano S, Takami A. Allogeneic hematopoietic cell transplantation efficacy in patients with Philadelphia chromosome-positive acute myeloid leukemia in complete remission. Bone Marrow Transplant. 2021 Jan;56(1):232-242.

• 矢野真吾(代表)
  効率的でドナーの負担軽減に資する末梢血幹細胞採取法の確立と非血縁者間末梢血幹細胞移植の治療成績向上のための研究（23FF1002）
  厚生労働省科学研究費.2023〜2025年


• 矢野真吾(分担)
  統合レジストリを活用したキャッスルマン病・TAFRO症候群における精密医療基盤の構築を目指す実用化研究
  日本医療研究開発機構臨床研究.治験推進研究事業2022〜2025 年.


• 矢野真吾(分担)
  t(8;21)およびinv(16)陽性AYA・若年成人急性骨髄性白血病に対する微小残存病変を指標とするゲムツズマブ・オゾガマイシン治療介入の有効性と安全性を評価する研究
  日本医療研究開発機構臨床研究.革新的がん医療実用化研究事業.2020〜2023年.


• 矢野真吾(分担)
  免疫チェックポイント阻害薬の安全な使用に資する irAE 心筋障害スクリーニン グ手法と危険因子の探索研究 ( An exploratory study for safe use of immune checkpoint inhibitors against irAE myocardial disorders )
  日本医療研究開発機構臨床研究.革新的がん医療実用化研究事業. 2020〜2022年.


• 石井敬人
  白血病における第三世代液体生検の社会実装に向けた基盤研究
  COI若手連携研究ファンド.　2020〜2023年

https://jikei-oncolhematol.com/